[HTML][HTML] Biomarker driven phase II clinical trial of trametinib in relapsed/refractory multiple myeloma with sequential addition of the AKT inhibitor, GSK2141795 at time …
Activating mutations of the MAPK pathway are reported in over half of myeloma tumors.
Experience with MEK inhibitors in solid tumors suggest that although tumors harboring …
Experience with MEK inhibitors in solid tumors suggest that although tumors harboring …
Biomarker Driven Phase II Clinical Trial of Trametinib in Relapsed/Refractory Multiple Myeloma with Sequential Addition of the AKT Inhibitor, GSK2141795 at Time of …
S Trudel, NJ Bahlis, CP Venner, AE Hay, O Kis… - 2016 - ashpublications.org
Activating mutations of the MAPK pathway are reported in over half of myeloma tumors.
Experience with MEK inhibitors in solid tumors suggest that although tumors harboring …
Experience with MEK inhibitors in solid tumors suggest that although tumors harboring …